HMGB2 is a potential diagnostic marker and therapeutic target for liver fibrosis and cirrhosis.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
06
04
2023
accepted:
23
08
2023
medline:
7
11
2023
pubmed:
6
11
2023
entrez:
6
11
2023
Statut:
epublish
Résumé
High mobility group proteins 1 and 2 (HMGB1 and HMGB2) are 80% conserved in amino acid sequence. The function of HMGB1 in inflammation and fibrosis has been extensively characterized. However, an unaddressed central question is the role of HMGB2 on liver fibrosis. In this study, we provided convincing evidence that the HMGB2 expression was significantly upregulated in human liver fibrosis and cirrhosis, as well as in several mouse liver fibrosis models. The carbon tetrachloride (CCl4) induced liver fibrosis mouse model was used. AAV8-Hmgb2 was utilized to overexpress Hmgb2 in the liver, while Hmgb2-/- mice were used for loss of function experiments. The HMGB2 inhibitor inflachromene and liposome-shHMGB2 (lipo-shHMGB2) were employed for therapeutic intervention. The serum HMGB2 levels were also markedly elevated in patients with liver fibrosis and cirrhosis. Deletion of Hmgb2 in Hmgb2-/- mice or inhibition of HMGB2 in mice using a small molecule ICM slowed the progression of CCl4-induced liver fibrosis despite constant HMGB1 expression. In contrast, AAV8-mediated overexpression of Hmgb2 enchanced CCl4-incuded liver fibrosis. Primary hepatic stellate cells (HSCs) isolated from Hmgb2-/- mice showed significantly impaired transdifferentiation and diminished activation of α-SMA, despite a modest induction of HMGB1 protein. RNA-seq analysis revealed the induction of top 45 CCl4-activated genes in multiple signaling pathways including integrin signaling and inflammation. The activation of these genes by CCl4 were abolished in Hmgb2-/- mice or in ICM-treated mice. These included C-X3-C motif chemokine receptor 1 (Cx3cr1) associated with inflammation, cyclin B (Ccnb) associated with cell cycle, DNA topoisomerase 2-alpha (Top2a) associated with intracellular component, and fibrillin (Fbn) and fibromodulin (Fmod) associated with extracellular matrix. We conclude that HMGB2 is indispensable for stellate cell activation. Therefore, HMGB2 may serve as a potential therapeutic target to prevent HSC activation during chronic liver injury. The blood HMGB2 level may also serve as a potential diagnostic marker to detect early stage of liver fibrosis and cirrhosis in humans.
Sections du résumé
BACKGROUND
High mobility group proteins 1 and 2 (HMGB1 and HMGB2) are 80% conserved in amino acid sequence. The function of HMGB1 in inflammation and fibrosis has been extensively characterized. However, an unaddressed central question is the role of HMGB2 on liver fibrosis. In this study, we provided convincing evidence that the HMGB2 expression was significantly upregulated in human liver fibrosis and cirrhosis, as well as in several mouse liver fibrosis models.
METHODS
The carbon tetrachloride (CCl4) induced liver fibrosis mouse model was used. AAV8-Hmgb2 was utilized to overexpress Hmgb2 in the liver, while Hmgb2-/- mice were used for loss of function experiments. The HMGB2 inhibitor inflachromene and liposome-shHMGB2 (lipo-shHMGB2) were employed for therapeutic intervention.
RESULTS
The serum HMGB2 levels were also markedly elevated in patients with liver fibrosis and cirrhosis. Deletion of Hmgb2 in Hmgb2-/- mice or inhibition of HMGB2 in mice using a small molecule ICM slowed the progression of CCl4-induced liver fibrosis despite constant HMGB1 expression. In contrast, AAV8-mediated overexpression of Hmgb2 enchanced CCl4-incuded liver fibrosis. Primary hepatic stellate cells (HSCs) isolated from Hmgb2-/- mice showed significantly impaired transdifferentiation and diminished activation of α-SMA, despite a modest induction of HMGB1 protein. RNA-seq analysis revealed the induction of top 45 CCl4-activated genes in multiple signaling pathways including integrin signaling and inflammation. The activation of these genes by CCl4 were abolished in Hmgb2-/- mice or in ICM-treated mice. These included C-X3-C motif chemokine receptor 1 (Cx3cr1) associated with inflammation, cyclin B (Ccnb) associated with cell cycle, DNA topoisomerase 2-alpha (Top2a) associated with intracellular component, and fibrillin (Fbn) and fibromodulin (Fmod) associated with extracellular matrix.
CONCLUSION
We conclude that HMGB2 is indispensable for stellate cell activation. Therefore, HMGB2 may serve as a potential therapeutic target to prevent HSC activation during chronic liver injury. The blood HMGB2 level may also serve as a potential diagnostic marker to detect early stage of liver fibrosis and cirrhosis in humans.
Identifiants
pubmed: 37930124
doi: 10.1097/HC9.0000000000000299
pii: 02009842-202311010-00024
pmc: PMC10629741
pii:
doi:
Substances chimiques
HMGB1 Protein
0
HMGB2 Protein
0
Transcription Factors
0
Fmod protein, mouse
0
Fibromodulin
126468-95-9
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK034989
Pays : United States
Organisme : NIAAA NIH HHS
ID : P50 AA011999
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
J Biol Chem. 2010 Aug 6;285(32):24871-81
pubmed: 20516075
Am J Respir Crit Care Med. 2004 Dec 15;170(12):1310-6
pubmed: 15374839
Hepatology. 2014 Jul;60(1):146-57
pubmed: 24492981
Development. 2001 Apr;128(8):1265-73
pubmed: 11262228
Hepatol Commun. 2017 Aug;1(6):513-523
pubmed: 29104954
PLoS One. 2012;7(4):e35510
pubmed: 22539975
Hepatology. 2017 Oct;66(4):1183-1196
pubmed: 28407375
Nat Commun. 2014 Jul 21;5:4451
pubmed: 25043713
J Cell Mol Med. 2006 Jan-Mar;10(1):76-99
pubmed: 16563223
Hepatol Res. 2011 Mar;41(3):199-208
pubmed: 21338451
J Biol Chem. 2007 Apr 6;282(14):10405-13
pubmed: 17317656
Hepatology. 2017 Feb;65(2):604-615
pubmed: 27770549
Nat Biotechnol. 2008 Apr;26(4):431-42
pubmed: 18376398
Gut. 2005 Jan;54(1):142-51
pubmed: 15591520
Expert Rev Gastroenterol Hepatol. 2011 Apr;5(2):179-87
pubmed: 21476913
Hepatology. 2003 Oct;38(4):879-89
pubmed: 14512875
Hepatology. 2014 Sep;60(3):919-30
pubmed: 24619556
Nat Chem Biol. 2014 Dec;10(12):1055-60
pubmed: 25306442
Mol Cell Biol. 2002 Apr;22(8):2810-20
pubmed: 11909973
FEBS Lett. 2011 May 6;585(9):1269-75
pubmed: 21459093
Gastroenterology. 2015 May;148(5):1012-1023.e14
pubmed: 25701738
Hepatology. 2018 May;67(5):1768-1783
pubmed: 29140550
Hepatology. 2015 Jan;61(1):129-40
pubmed: 25132354
Int J Biol Sci. 2011;7(9):1273-86
pubmed: 22110380
JCI Insight. 2017 Nov 2;2(21):
pubmed: 29093267
Am J Pathol. 2016 Nov;186(11):2909-2920
pubmed: 27664470
Trends Biochem Sci. 2001 Mar;26(3):167-74
pubmed: 11246022
J Cell Sci. 2016 Nov 15;129(22):4305-4316
pubmed: 27672022
Nucleic Acids Res. 2012 Jun;40(11):4850-60
pubmed: 22362755
Autoimmunity. 2009 May;42(4):308-10
pubmed: 19811285
Nat Rev Gastroenterol Hepatol. 2010 Aug;7(8):425-36
pubmed: 20585339
Gastroenterology. 2012 Mar;142(3):612-621.e5
pubmed: 22138190
Trends Biochem Sci. 2012 Dec;37(12):553-62
pubmed: 23153957
Hepatology. 2015 Feb;61(2):497-505
pubmed: 25212631
Lab Invest. 2008 Oct;88(10):1090-100
pubmed: 18663351
Clin Cancer Res. 2010 Nov 15;16(22):5511-21
pubmed: 20851854
Sci Rep. 2016 Feb 03;6:20559
pubmed: 26838806
Hepatol Commun. 2017 Oct;1(8):816-830
pubmed: 29218329
Mol Cancer Ther. 2016 Oct;15(10):2294-2301
pubmed: 27486225
Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1181-6
pubmed: 19139395
Cell Tissue Res. 2012 Jan;347(1):245-56
pubmed: 22006249
Pharm Res. 2016 Feb;33(2):404-16
pubmed: 26428671
Mol Cell Biol. 1998 Aug;18(8):4471-87
pubmed: 9671457
Am J Physiol Gastrointest Liver Physiol. 2013 Sep 1;305(5):G364-74
pubmed: 23812039
Mol Ther. 2008 Jun;16(6):1073-80
pubmed: 18414476
Front Physiol. 2016 Oct 25;7:491
pubmed: 27826254
Hepatol Commun. 2019 Feb 20;3(4):542-557
pubmed: 30976744
Mol Pharmacol. 2017 Mar;91(3):189-196
pubmed: 28003426